BCAB Stock Analysis: Buy, Sell, or Hold?
BCAB - BioAtla, Inc. Common Stock
$4.19
0.11 (2.57%)
▲
5d:
+18.03%
30d:
+18.7%
90d:
+3012.93%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When BCAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BCAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BCAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BCAB is currently trading at $4.19, which is considered extended relative to its 30-day fair value range of $3.44 to $3.92.
Technical Outlook: Technically, BCAB is in a strong uptrend. The price is approaching resistance at $4.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BCAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+138.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BCAB is in a strong uptrend. The price is approaching resistance at $4.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BCAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+138.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.44 -
$3.92
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+6.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 138.7% below Wall St target ($10.00)
Trading Range Analysis
30-Day Trading Range
$3.44 -
$3.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.45
Resistance Level
$4.30
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.13
Wall Street Target
$10.00
(+138.7%)
Revenue Growth (YoY)
31.6%
Share & Embed Analysis
Last updated: July 02, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
